<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Pitted keratolysis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Pitted keratolysis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Pitted keratolysis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Benjamin Barankin, MD, FRCPC
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alexander KC Leung, MBBS, FRCPC, FRCP (UK &amp; Ireland), FRCPCH, FAAP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Ted Rosen, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Abena O Ofori, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Mar 06, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1838576290">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pitted keratolysis (also known as keratolysis sulcata, keratolysis plantare sulcatum, and ringed keratolysis) is a superficial bacterial skin infection confined to the stratum corneum. Clinically, pitted keratolysis is characterized by malodor and multifocal, discrete, superficial crateriform pits and superficial erosions primarily affecting pressure-bearing areas of the plantar surface of the feet  (
         <a class="graphic graphic_picture graphicRef112093 graphicRef112094 graphicRef112095 graphicRef112096" href="/z/d/graphic/112093.html" rel="external">
          picture 1A-D
         </a>
         ). Topical antibiotic therapy usually leads to resolution of the disease.
        </p>
        <p>
         The clinical features, diagnosis, and management of pitted keratolysis will be reviewed here.
        </p>
        <p class="headingAnchor" id="H191658136">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pitted keratolysis has a worldwide distribution but occurs most frequently in tropical and temperate regions with high humidity levels [
         <a href="#rid1">
          1
         </a>
         ]. The disorder is not uncommon; in a
         <sup>
         </sup>
         mass examination of 4325 Korean industrial workers in 1981, 1.5 percent had pitted keratolysis [
         <a href="#rid2">
          2
         </a>
         ]. In another study, 18 (2.6 percent) of 682 students (aged 14 to 25 years) from two Turkish boarding schools had pitted keratolysis
         <sup>
         </sup>
         [
         <a href="#rid3">
          3
         </a>
         ]. There is no racial predilection [
         <a href="#rid4">
          4-6
         </a>
         ].
        </p>
        <p>
         Pitted keratolysis is most common in the age group of 21 to 30 years, with approximately 80 to 96 percent of affected patients between 10 and 40 years of age [
         <a href="#rid7">
          7,8
         </a>
         ]. The male-to-female ratio is approximately 4:1 [
         <a href="#rid8">
          8,9
         </a>
         ]. Presumably, the male predominance is due to more frequent use of occlusive footwear among males and females' better foot hygiene [
         <a href="#rid8">
          8,10-12
         </a>
         ].
        </p>
        <p>
         Occupations at risk include athletes, industrial workers, miners, farmers, marine workers, and military personnel [
         <a href="#rid13">
          13-16
         </a>
         ]. Predisposing factors include hyperhidrosis, prolonged use of occlusive footwear such as vinyl shoes or rubber boots, thickened skin of soles and palms, increased skin surface pH, hot and humid weather, poor foot hygiene, obesity, diabetes mellitus, and immunodeficiency [
         <a href="#rid11">
          11,17,18
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3098508374">
         <span class="h1">
          MICROBIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pitted keratolysis is most commonly caused by
         <em>
          Corynebacterium
         </em>
         species,
         <em>
          Kytococcus sedentarius
         </em>
         (formerly known as
         <em>
          Micrococcus sedentarius
         </em>
         ),
         <sup>
         </sup>
         <em>
          Dermatophilus congolensis
         </em>
         ,
         <em>
          Streptomyces
         </em>
         , and
         <em>
          Actinomyces
         </em>
         <em>
          keratolytica
         </em>
         [
         <a href="#rid19">
          19-22
         </a>
         ]. Less commonly, the condition can be caused by
         <em>
          Klebsiella
         </em>
         ,
         <em>
          Pseudomonas
         </em>
         ,
         <em>
          Acinetobacter
         </em>
         , and
         <em>
          Clostridium
         </em>
         species [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1540932955">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Under optimal conditions of a moist and warm environment, the causative bacteria proliferate and produce extracellular proteases that enable them to digest keratin and dissolve the stratum corneum, resulting in the characteristic tunnel-like pits or craters [
         <a href="#rid12">
          12,19,21,23
         </a>
         ].
         <sup>
         </sup>
         The foul odor is due to sulfur compounds (eg, thiols, sulfides, and thioesters) produced by the bacteria [
         <a href="#rid6">
          6,22,23
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2501222317">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pitted keratolysis usually presents with clusters of multiple, conspicuous, discrete, superficial, circular, "punched-out" pits  (
         <a class="graphic graphic_picture graphicRef112093 graphicRef112094 graphicRef112095" href="/z/d/graphic/112093.html" rel="external">
          picture 1A-C
         </a>
         ) [
         <a href="#rid17">
          17,24,25
         </a>
         ]. Some pits have a brownish color and may give the foot a dirty appearance [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
         The pits range from 0.5 to 7 mm in diameter and are 1 to 2 mm deep [
         <a href="#rid17">
          17,19,27
         </a>
         ]. The pits may coalesce into bigger, irregular erosions, sulci, and crater-like lesions  (
         <a class="graphic graphic_picture graphicRef112096 graphicRef81393" href="/z/d/graphic/112096.html" rel="external">
          picture 1D-E
         </a>
         ) [
         <a href="#rid22">
          22,28
         </a>
         ]. The findings become more prominent when the foot is wet or soaked in water [
         <a href="#rid14">
          14,26,29
         </a>
         ].
        </p>
        <p>
         Sites of predilection include the pressure-bearing areas of the foot, such as the plantar aspect of the toe, the ball of the foot, and the heel [
         <a href="#rid17">
          17,24,25
         </a>
         ].
         <sup>
         </sup>
         The condition is usually bilateral but may be asymmetrical with one foot more affected than the other [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         Additional characteristic features include a "rotten" odor and slimy texture of the skin on the feet [
         <a href="#rid6">
          6,11
         </a>
         ]. Hyperhidrosis and maceration are frequently present [
         <a href="#rid17">
          17,26,30
         </a>
         ]. Erythematous to violaceous macules may also be seen [
         <a href="#rid4">
          4,5
         </a>
         ].
        </p>
        <p>
         Pitted keratolysis is typically asymptomatic; however, pruritus, irritation, burning sensations, and pain during ambulation occasionally occur [
         <a href="#rid9">
          9-11
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H474871467">
         <span class="h2">
          Clinical variants
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to the classic clinical presentation, there are several less common clinical variants:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Involvement of nonweightbearing areas
         </strong>
         – Rarely, pitted keratolysis occurs on nonweightbearing acral skin (eg, instep and arch of the foot, dorsal aspect of the toe, or palms) with or without concomitant involvement of the typical sites on the feet [
         <a href="#rid1">
          1,4,8,25
         </a>
         ]. Involvement of the palm is more common in certain professions (eg, paddy field workers) [
         <a href="#rid13">
          13
         </a>
         ]. On the palms, pitted keratolysis tends to manifest as scaly collarettes or ringed keratolysis rather than pits [
         <a href="#rid10">
          10,22,29,31
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Painful plaque-like variant
         </strong>
         – A painful plaque-like variant characterized by tender erythematous to violaceous plaques with typical superficial pits and shallow erosions has been described in children and adults  (
         <a class="graphic graphic_picture graphicRef112097" href="/z/d/graphic/112097.html" rel="external">
          picture 2
         </a>
         ) [
         <a href="#rid32">
          32,33
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Large crateriform depressions
         </strong>
         – Rarely, pitted keratolysis presents as large crateriform depressions [
         <a href="#rid34">
          34
         </a>
         ]. Walking barefoot on wet earth may predispose to this variant.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Corynebacterial triad
         </strong>
         – A corynebacterial triad of pitted keratolysis, erythrasma, and trichomycosis axillaris has been described [
         <a href="#rid8">
          8,9,14,35
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1658417030">
         <span class="h1">
          HISTOPATHOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Histologic examination shows pits or erosions confined to the stratum corneum [
         <a href="#rid24">
          24
         </a>
         ]. The pits and erosions have sharply inclined walls and a flat base consisting of a thin layer or localized absence of stratum corneum. Microorganisms with coccoid and filamentous forms can be detected in a scraping or thin-shaved specimen of the stratum corneum using a Gram stain, hematoxylin and eosin (H&amp;E) stain, methenamine silver stain, or periodic acid-Schiff (PAS) stain [
         <a href="#rid4">
          4,36
         </a>
         ].
        </p>
        <p>
         Electron microscopy demonstrates tunnel openings of the crateriform pits where the causative bacteria reside [
         <a href="#rid37">
          37
         </a>
         ]. Bacteria may be seen intercellularly on the surface of the stratum corneum and intracorneocytically in the horny layer [
         <a href="#rid5">
          5,15,24,28
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3445177962">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The physical examination is usually sufficient for diagnosis, based upon the recognition of the distinctive clinical appearance of pitted keratolysis and the associated pungent odor. Physical findings that strongly support a diagnosis of pitted keratolysis include clusters of multiple conspicuous, discrete, white to yellow, superficial, 0.5 to 7 mm crateriform pits and superficial erosions on pressure-bearing areas of the soles (eg, ball and heel of the foot)  (
         <a class="graphic graphic_picture graphicRef112093 graphicRef112094 graphicRef112095 graphicRef112096" href="/z/d/graphic/112093.html" rel="external">
          picture 1A-D
         </a>
         ) [
         <a href="#rid17">
          17
         </a>
         ]. Less frequently, physical examination reveals bigger, irregular erosions, sulci, crater-like lesions, and plaques. Sliminess of the skin, hyperhidrosis, and maceration are common additional findings.
        </p>
        <p>
         Dermoscopic examination can facilitate visualization of pits and pit walls [
         <a href="#rid38">
          38
         </a>
         ]. Examination with a Wood's lamp may reveal coral red fluorescence as may be seen in erythrasma, but this finding is not consistently present [
         <a href="#rid5">
          5,10
         </a>
         ].
        </p>
        <p>
         Laboratory studies usually are not necessary. A potassium hydroxide preparation to detect fungus can be performed if there is scale or other findings suggestive of concomitant tinea pedis. A culture is rarely indicated but may show gram-positive bacilli or coccobacilli [
         <a href="#rid19">
          19
         </a>
         ]. Culture requires special media such as brain heart infusion agar for aerobic culture and Robertson's meat medium for anaerobic culture [
         <a href="#rid13">
          13,26
         </a>
         ].
        </p>
        <p>
         A skin biopsy is seldom necessary for diagnosis. If performed, the biopsy will reveal the characteristic histopathologic features of pitted keratolysis. A superficial shave biopsy of the stratum corneum is sufficient [
         <a href="#rid36">
          36
         </a>
         ]. (See
         <a class="local">
          'Histopathology'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3592024848">
         <span class="h1">
          ADDITIONAL EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Examination of the intertriginous areas (axilla, groin) is prudent in patients with pitted keratolysis, as it may identify coexisting corynebacterial infections such as erythrasma and trichomycosis axillaris [
         <a href="#rid26">
          26
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4031.html" rel="external">
          "Erythrasma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1362326836">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis includes a variety of disorders that may present with punctate or hyperkeratotic lesions on the feet  (
         <a class="graphic graphic_table graphicRef112214" href="/z/d/graphic/112214.html" rel="external">
          table 1
         </a>
         ). Examples include [
         <a href="#rid6">
          6,19,26
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Aquagenic palmoplantar keratoderma  (
         <a class="graphic graphic_picture graphicRef112101" href="/z/d/graphic/112101.html" rel="external">
          picture 3
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Arsenical keratosis (see
         <a class="medical medical_review" href="/z/d/html/2778.html" rel="external">
          "Arsenic exposure and chronic poisoning", section on 'Dermatologic'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Darier disease  (
         <a class="graphic graphic_picture graphicRef112103" href="/z/d/graphic/112103.html" rel="external">
          picture 4
         </a>
         ) (see
         <a class="medical medical_review" href="/z/d/html/15462.html" rel="external">
          "Darier disease", section on 'Skin lesions'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dyshidrotic eczema  (
         <a class="graphic graphic_picture graphicRef112102" href="/z/d/graphic/112102.html" rel="external">
          picture 5
         </a>
         ) (see
         <a class="medical medical_review" href="/z/d/html/13657.html" rel="external">
          "Acute palmoplantar eczema (dyshidrotic eczema)", section on 'Clinical presentation'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Exfoliative keratolysis (see
         <a class="medical medical_review" href="/z/d/html/15512.html" rel="external">
          "Peeling skin syndromes", section on 'Keratolysis exfoliativa'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Focal acral hyperkeratosis
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Juvenile plantar dermatosis  (
         <a class="graphic graphic_picture graphicRef112099" href="/z/d/graphic/112099.html" rel="external">
          picture 6
         </a>
         ) (see
         <a class="medical medical_review" href="/z/d/html/1727.html" rel="external">
          "Overview of dermatitis (eczematous dermatoses)", section on 'Juvenile plantar dermatosis'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nevoid basal cell carcinoma syndrome  (
         <a class="graphic graphic_picture graphicRef112105" href="/z/d/graphic/112105.html" rel="external">
          picture 7
         </a>
         ) (see
         <a class="medical medical_review" href="/z/d/html/5340.html" rel="external">
          "Nevoid basal cell carcinoma syndrome (Gorlin syndrome)", section on 'Palmar-plantar pits'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Plantar warts  (
         <a class="graphic graphic_picture graphicRef112100" href="/z/d/graphic/112100.html" rel="external">
          picture 8
         </a>
         ) (see
         <a class="medical medical_review" href="/z/d/html/4029.html" rel="external">
          "Cutaneous warts (common, plantar, and flat warts)", section on 'Clinical features'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Porokeratosis (see
         <a class="medical medical_review" href="/z/d/html/13721.html" rel="external">
          "Porokeratosis", section on 'Porokeratosis plantaris palmaris et disseminata'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13721.html" rel="external">
          "Porokeratosis", section on 'Punctate porokeratosis'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Punctate palmoplantar keratoderma  (
         <a class="graphic graphic_picture graphicRef112104" href="/z/d/graphic/112104.html" rel="external">
          picture 9
         </a>
         ) (see
         <a class="medical medical_review" href="/z/d/html/110147.html" rel="external">
          "Palmoplantar keratoderma", section on 'Punctate palmoplantar keratoderma'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tinea pedis  (
         <a class="graphic graphic_picture graphicRef112098" href="/z/d/graphic/112098.html" rel="external">
          picture 10
         </a>
         ) (see
         <a class="medical medical_review" href="/z/d/html/4030.html" rel="external">
          "Dermatophyte (tinea) infections", section on 'Tinea pedis'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tungiasis (see
         <a class="medical medical_review" href="/z/d/html/3895.html" rel="external">
          "Skin lesions in the returning traveler", section on 'Tungiasis'
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         Often, the history and physical findings are sufficient to differentiate pitted keratolysis from these disorders. Key features of each disorder are reviewed in a table  (
         <a class="graphic graphic_table graphicRef112214" href="/z/d/graphic/112214.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H864791098">
         <span class="h1">
          MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Data on the management of pitted keratolysis are limited, contributing to uncertainty about the ideal approach to treatment [
         <a href="#rid30">
          30
         </a>
         ]. Most patients can be effectively managed with topical antimicrobial therapy and adjunctive measures to improve foot hygiene. Oral antibiotic therapy is reserved for resistant disease.
        </p>
        <p class="headingAnchor" id="H3987181826">
         <span class="h2">
          First-line therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Topical antibiotics are the first-line treatments for pitted keratolysis. The topical antimicrobial
         <a class="drug drug_general" data-topicid="8811" href="/z/d/drug information/8811.html" rel="external">
          benzoyl peroxide
         </a>
         is an alternative first-line treatment.
        </p>
        <p class="headingAnchor" id="H3863987753">
         <span class="h3">
          Topical antibiotics
         </span>
         <span class="headingEndMark">
          —
         </span>
         Topical antibiotics with activity against
         <em>
          Corynebacterium
         </em>
         and the other organisms responsible for pitted keratolysis (
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9668" href="/z/d/drug information/9668.html" rel="external">
          mupirocin
         </a>
         , and
         <a class="drug drug_general" data-topicid="8648" href="/z/d/drug information/8648.html" rel="external">
          fusidic acid
         </a>
         ) are our preferred first-line therapies based upon limited data from case reports and uncontrolled studies that suggest efficacy and the relative safety of these agents [
         <a href="#rid10">
          10-12,19,28,39
         </a>
         ]. As an example, in an uncontrolled study of 97 patients treated with twice-daily application of erythromycin 3% gel, all patients had a complete remission of skin lesions within 10 days [
         <a href="#rid12">
          12
         </a>
         ]. Fusidic acid is not available in the United States.
        </p>
        <p>
         Topical
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9668" href="/z/d/drug information/9668.html" rel="external">
          mupirocin
         </a>
         , or
         <a class="drug drug_general" data-topicid="8648" href="/z/d/drug information/8648.html" rel="external">
          fusidic acid
         </a>
         is applied twice daily until clinical resolution. Topical
         <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">
          minocycline
         </a>
         presumably would be effective as well. A complete response is expected within one to eight weeks, with patients usually responding within two to four weeks [
         <a href="#rid6">
          6,11
         </a>
         ]. Skin irritation is an infrequent adverse effect of topical antibiotic use. Examples of rare side effects include contact dermatitis and
         <em>
          Clostridioides difficile
         </em>
         colitis.
        </p>
        <p class="headingAnchor" id="H3235728476">
         <span class="h3">
          Other antimicrobial agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8811" href="/z/d/drug information/8811.html" rel="external">
          Benzoyl peroxide
         </a>
         , an antimicrobial agent with keratolytic properties, is sometimes used as therapy for pitted keratolysis [
         <a href="#rid14">
          14
         </a>
         ]. Benzoyl peroxide has been used alone or in combination with topical antibiotics, such as
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         [
         <a href="#rid6">
          6,23
         </a>
         ].
        </p>
        <p>
         Use of combination products containing
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         and
         <a class="drug drug_general" data-topicid="8811" href="/z/d/drug information/8811.html" rel="external">
          benzoyl peroxide
         </a>
         has been suggested based upon the idea that both compounds have antibacterial properties, and the keratolytic properties of benzoyl peroxide facilitate penetration of clindamycin into the skin [
         <a href="#rid6">
          6
         </a>
         ]. In an uncontrolled study of four patients with pitted keratolysis, once-daily application of clindamycin 1%-benzoyl peroxide 5% gel for one to two months (with topical aluminium chloride hexahydrate solution added to the regimen after the first month) led to resolution of disease in all patients [
         <a href="#rid6">
          6
         </a>
         ]. However, a study that compared outcomes of treatment with benzoyl peroxide alone, clindamycin alone, and combined application of benzoyl peroxide and clindamycin in 44 patients with pitted keratolysis did not find statistically significant differences in efficacy among the three regimens [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8811" href="/z/d/drug information/8811.html" rel="external">
          Benzoyl peroxide
         </a>
         is applied once or twice daily until clinical resolution. As with topical antibiotics, significant improvement is expected within a few weeks. Skin irritation is a potential side effect.
        </p>
        <p>
         A trial in 125 adults with pitted keratolysis randomly assigned subjects to either twice-daily application of
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         4% gel or twice-daily cleansing with
         <a class="drug drug_general" data-topicid="9244" href="/z/d/drug information/9244.html" rel="external">
          chlorhexidine
         </a>
         4% scrub for four weeks [
         <a href="#rid41">
          41
         </a>
         ]. At the end of treatment, complete resolution occurred at similar rates in patients in the erythromycin and chlorhexidine groups (81 and 74 percent, respectively). Chlorhexidine was left on the skin for two minutes prior to rinsing.
        </p>
        <p class="headingAnchor" id="H3655005321">
         <span class="h2">
          Adjunctive measures
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although the efficacy of such interventions has not been studied, improvement of foot hygiene and treatment of concomitant hyperhidrosis are suggested as methods to promote resolution of pitted keratolysis and minimize risk for reinfection [
         <a href="#rid5">
          5,12,27
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2615849996">
         <span class="h3">
          Foot hygiene
         </span>
         <span class="headingEndMark">
          —
         </span>
         We encourage patients to engage in the following measures:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Wear cotton or absorbent synthetic socks and change socks frequently
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Wash socks after wearing with soap and water at temperatures &gt;60°C
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Wash feet with soap and water at least once daily
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Clean and thoroughly dry feet after exercise or bathing
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Avoid prolonged wearing of occlusive shoes; preferentially wear nonocclusive shoes or ventilating occupational shoes
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Wear properly fitted footwear to reduce friction on the feet
        </p>
        <p>
        </p>
        <p>
         When necessary (eg, patients with frequent recurrences or recalcitrant disease), special ultraviolet C devices can be used to kill the bacteria in footwear.
        </p>
        <p class="headingAnchor" id="H3689535253">
         <span class="h3">
          Treatment of hyperhidrosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Given that sweating and moisture may contribute to pitted keratolysis, patients with associated hyperhidrosis may benefit from treatment of this condition. Topical
         <a class="drug drug_general" data-topicid="8612" href="/z/d/drug information/8612.html" rel="external">
          aluminum chloride hexahydrate
         </a>
         solution (typically 20%, but lower concentrations are helpful as well) applied at night to completely dry soles or palms and washed off in the morning is typically used as first-line treatment for hyperhidrosis [
         <a href="#rid30">
          30
         </a>
         ]. For severe and persistent hyperhidrosis that may render pitted keratolysis resistant to treatment, other interventions for hyperhidrosis, such as injections of botulinum toxin, oral anticholinergics, and iontophoresis, are options [
         <a href="#rid1">
          1,19,42,43
         </a>
         ]. Topical
         <a class="drug drug_general" data-topicid="8496" href="/z/d/drug information/8496.html" rel="external">
          glycopyrrolate
         </a>
         , an anticholinergic agent used in the treatment of hyperhidrosis, may also be useful. In a case series, all three patients treated with glycopyrrolate 2% cream for pitted keratolysis had marked improvement [
         <a href="#rid44">
          44
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5567.html" rel="external">
          "Primary focal hyperhidrosis", section on 'Palmar or plantar hyperhidrosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H828798527">
         <span class="h2">
          Refractory disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Oral antibiotic therapy is typically reserved for pitted keratolysis that fails to respond to topical therapy. We typically use
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         or
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         according to the following regimens:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          Clindamycin
         </a>
         :
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Adults – 150 to 300 mg four times per day
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Children – 10 to 25 mg/kg per day in three to four divided doses (maximum 300 mg per dose)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          Erythromycin
         </a>
         :
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Base or stearate, adults – 250 to 500 mg four times per day
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Base or stearate, children – 30 to 50 mg/kg per day in four divided doses (maximum 2 g per day)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Ethylsuccinate, adults – 400 to 800 mg four times per day
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Ethylsuccinate, children – 30 to 50 mg/kg per day in four divided doses (maximum 3 g per day)
        </p>
        <p>
        </p>
        <p>
         The oral antibiotic should be prescribed for at least 10 days; the duration of treatment depends on disease severity and response to treatment [
         <a href="#rid9">
          9,14,29
         </a>
         ]. (See
         <a class="local">
          'Follow-up'
         </a>
         below.)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          Clindamycin
         </a>
         is generally well tolerated. Possible adverse reactions include nausea, vomiting, abdominal pain, diarrhea, metallic taste, and rash. Less common adverse reactions include
         <em>
          C. difficile
         </em>
         colitis, polyarthritis, anaphylaxis, blood dyscrasias, hepatotoxicity, and renal dysfunction.
        </p>
        <p>
         Possible adverse reactions to
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         include nausea, vomiting, abdominal pain, flatulence, diarrhea, headache, pruritus, and rash. Less common but more serious side effects may include allergic reactions, anaphylaxis,
         <em>
          C. difficile
         </em>
         colitis, liver dysfunction, tinnitus, reversible deafness, prolonged QT intervals including torsades de pointes, and interstitial nephritis. Exposure to erythromycin through breastfeeding may increase the risk of pyloric stenosis in the infant. (See
         <a class="medical medical_review" href="/z/d/html/5890.html" rel="external">
          "Infantile hypertrophic pyloric stenosis", section on 'Macrolide antibiotics'
         </a>
         .)
        </p>
        <p>
         Patients with contraindications to
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         and
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         or who fail to improve on these agents may be treated with oral tetracyclines. Adults may be treated with
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         (100 mg once or twice daily),
         <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">
          minocycline
         </a>
         (100 mg once or twice daily), or
         <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">
          tetracycline
         </a>
         (250 to 500 mg four times daily). Tetracyclines should not
         <strong>
         </strong>
         be given to children under nine years of age because of the risk for permanent tooth discoloration and reduced bone growth.
        </p>
        <p>
         Adverse effects of oral tetracyclines include nausea, vomiting, diarrhea, candidal superinfection, and photosensitivity.
         <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">
          Minocycline
         </a>
         is the least photosensitizing of these agents, but it may cause vertigo and a lupus-like syndrome. If not swallowed with sufficient water, tetracyclines can cause esophagitis and esophageal erosions.
        </p>
        <p class="headingAnchor" id="H3799235934">
         <span class="h1">
          PREVENTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Measures to improve foot hygiene may aid in the prevention of pitted keratolysis [
         <a href="#rid12">
          12,27,30
         </a>
         ]. (See
         <a class="local">
          'Adjunctive measures'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H736210615">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Untreated, pitted keratolysis may last for years with spontaneous remissions and exacerbations [
         <a href="#rid8">
          8
         </a>
         ]. With proper treatment, the condition usually resolves in two to four weeks [
         <a href="#rid6">
          6,19
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H405116835">
         <span class="h1">
          FOLLOW-UP
         </span>
         <span class="headingEndMark">
          —
         </span>
         Periodic follow-up during treatment is helpful to assess therapeutic response and determine the ideal duration of treatment.
        </p>
        <p class="headingAnchor" id="H2747294153">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Microbiology
         </strong>
         – Pitted keratolysis is a superficial bacterial skin infection confined to the stratum corneum that most often occurs on the soles of the feet.
         <em>
          Corynebacterium
         </em>
         species,
         <em>
          Kytococcus sedentarius
         </em>
         (formerly known as
         <em>
          Micrococcus sedentarius
         </em>
         ),
         <sup>
         </sup>
         <em>
          Dermatophilus congolensis
         </em>
         ,
         <em>
          Streptomyces
         </em>
         , and
         <em>
          Actinomyces
         </em>
         <em>
          keratolytica
         </em>
         are the most common causative organisms. (See
         <a class="local">
          'Microbiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology and risk factors
         </strong>
         – Pitted keratolysis primarily occurs in young adults and affects males more frequently than females. Risk factors include hyperhidrosis, prolonged use of occlusive footwear, thickened skin of soles and palms, increased skin surface pH, hot and humid weather, poor foot hygiene, obesity, diabetes mellitus, and immunodeficiency. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical manifestations
         </strong>
         – The most common clinical findings of pitted keratolysis are clusters of discrete, superficial, round, punched-out pits and erosions on weight-bearing areas of the soles of the feet  (
         <a class="graphic graphic_picture graphicRef112093 graphicRef112094 graphicRef112095 graphicRef112096" href="/z/d/graphic/112093.html" rel="external">
          picture 1A-D
         </a>
         ). Patients often have an associated pungent odor from the feet and a slimy texture on the skin of the feet. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – Pitted keratolysis usually can be diagnosed based solely on the physical examination. Culture and skin biopsy usually are not necessary. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         :
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Antimicrobial therapy
         </strong>
         – We suggest topical antibiotic therapy rather than oral antibiotic therapy for first-line treatment of pitted keratolysis (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Examples of effective topical antibiotics include
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9668" href="/z/d/drug information/9668.html" rel="external">
          mupirocin
         </a>
         , and
         <a class="drug drug_general" data-topicid="8648" href="/z/d/drug information/8648.html" rel="external">
          fusidic acid
         </a>
         .
         <a class="drug drug_general" data-topicid="8811" href="/z/d/drug information/8811.html" rel="external">
          Benzoyl peroxide
         </a>
         may also be an effective topical antimicrobial therapy. Patients who cannot be successfully treated with topical agents may respond to oral antibiotic therapy. (See
         <a class="local">
          'Management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Adjunctive measures
         </strong>
         – Interventions to improve foot hygiene may aid in promoting resolution of pitted keratolysis and minimizing risk for reinfection. Because hyperhidrosis is a risk factor for pitted keratolysis, treatment of hyperhidrosis is also likely to be beneficial. (See
         <a class="local">
          'Adjunctive measures'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Tamura BM, Cucé LC, Souza RL, Levites J. Plantar hyperhidrosis and pitted keratolysis treated with botulinum toxin injection. Dermatol Surg 2004; 30:1510.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eun HC, Park HB, Chun YH. Occupational pitted keratolysis. Contact Dermatitis 1985; 12:122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tuncel AA, Erbagci Z. Prevalence of skin diseases among male adolescent and post-adolescent boarding school students in Turkey. J Dermatol 2005; 32:557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh G, Naik CL. Pitted keratolysis. Indian J Dermatol Venereol Leprol 2005; 71:213.
          </a>
         </li>
         <li class="breakAll">
          http://emedicine.medscape.com/article/1053078-overview (Accessed on January 20, 2017).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vlahovic TC, Dunn SP, Kemp K. The use of a clindamycin 1%-benzoyl peroxide 5% topical gel in the treatment of pitted keratolysis: a novel therapy. Adv Skin Wound Care 2009; 22:564.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Narayani K, Gopinathan T, Lpe TP. Pitied Keratolysis. Indian J Dermatol Venereol Leprol 1981; 47:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pinto M, Hundi GK, Bhat RM, et al. Clinical and epidemiological features of coryneform skin infections at a tertiary hospital. Indian Dermatol Online J 2016; 7:168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blaise G, Nikkels AF, Hermanns-Lê T, et al. Corynebacterium-associated skin infections. Int J Dermatol 2008; 47:884.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greywal T, Cohen PR. Pitted keratolysis: successful management with mupirocin 2% ointment monotherapy. Dermatol Online J 2015; 21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaptanoglu AF, Yuksel O, Ozyurt S. Plantar pitted keratolysis: a study from non-risk groups. Dermatol Reports 2012; 4:e4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pranteda G, Carlesimo M, Pranteda G, et al. Pitted keratolysis, erythromycin, and hyperhidrosis. Dermatol Ther 2014; 27:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shenoi SD, Davis SV, Rao S, et al. Dermatoses among paddy field workers--a descriptive, cross-sectional pilot study. Indian J Dermatol Venereol Leprol 2005; 71:254.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Snoek EM, Ekkelenkamp MB, Suykerbuyk JC. Pitted keratolysis; physicians' treatment and their perceptions in Dutch army personnel. J Eur Acad Dermatol Venereol 2013; 27:1120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wohlrab J, Rohrbach D, Marsch WC. Keratolysis sulcata (pitted keratolysis): clinical symptoms with different histological correlates. Br J Dermatol 2000; 143:1348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bunyaratavej S, Leeyaphan C, Chanyachailert P, et al. Clinical manifestations, risk factors and quality of life in patients with pitted keratolysis: a cross-sectional study in cadets. Br J Dermatol 2018; 179:1220.
          </a>
         </li>
         <li class="breakAll">
          www.consultant360.com/articles/pitted-keratolysis (Accessed on February 02, 2017).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walling HW. Primary hyperhidrosis increases the risk of cutaneous infection: a case-control study of 387 patients. J Am Acad Dermatol 2009; 61:242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fernández-Crehuet P, Ruiz-Villaverde R. Pitted keratolysis: an infective cause of foot odour. CMAJ 2015; 187:519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gillum RL, Qadri SM, Al-Ahdal MN, et al. Pitted keratolysis: a manifestation of human dermatophilosis. Dermatologica 1988; 177:305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Longshaw CM, Wright JD, Farrell AM, Holland KT. Kytococcus sedentarius, the organism associated with pitted keratolysis, produces two keratin-degrading enzymes. J Appl Microbiol 2002; 93:810.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nordstrom KM, McGinley KJ, Cappiello L, et al. Pitted keratolysis. The role of Micrococcus sedentarius. Arch Dermatol 1987; 123:1320.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leung AK, Barankin B. Pitted Keratolysis. J Pediatr 2015; 167:1165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stanton RL, Schwartz RA. Pitted keratolysis: a common foot problem. Am Fam Physician 1983; 27:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takama H, Tamada Y, Yokochi K, Ikeya T. Pitted keratolysis: a discussion of two cases in non-weight-bearing areas. Acta Derm Venereol 1998; 78:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramsey ML. Pitted keratolysis: a common infection of active feet. Phys Sportsmed 1996; 24:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Luca JF, Adams BB, Yosipovitch G. Skin manifestations of athletes competing in the summer olympics: what a sports medicine physician should know. Sports Med 2012; 42:399.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Almeida HL Jr, Siqueira RN, Meireles Rda S, et al. Pitted keratolysis. An Bras Dermatol 2016; 91:106.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zaias N. Pitted and ringed keratolysis. A review and update. J Am Acad Dermatol 1982; 7:787.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bristow IR, Lee YL. Pitted keratolysis: a clinical review. J Am Podiatr Med Assoc 2014; 104:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Emmerson RW, Jones EW. Ringed keratolysis of the palms. Trans St Johns Hosp Dermatol Soc 1967; 53:165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lamberg SI. Symptomatic pitted keratolysis. Arch Dermatol 1969; 100:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah AS, Kamino H, Prose NS. Painful, plaque-like, pitted keratolysis occurring in childhood. Pediatr Dermatol 1992; 9:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sehgal VN, Ramesh V. Crateriform depression--an unusual clinical expression of pitted keratolysis. Dermatologica 1983; 166:209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shelley WB, Shelley ED. Coexistent erythrasma, trichomycosis axillaris, and pitted keratolysis: an overlooked corynebacterial triad? J Am Acad Dermatol 1982; 7:752.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takama H, Tamada Y, Yano K, et al. Pitted keratolysis: clinical manifestations in 53 cases. Br J Dermatol 1997; 137:282.
          </a>
         </li>
         <li class="breakAll">
          Sheth AP. Pitted keratolysis, erythrasma and erysipeloid. In: Harper’s Textbook of Pediatric Dermatology, Irvine AD, Hoeger PH, Yan AC (Eds), Wiley-Blackwell, 2011. p.56.1.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lockwood LL, Gehrke S, Navarini AA. Dermoscopy of Pitted Keratolysis. Case Rep Dermatol 2010; 2:146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Papaparaskevas J, Stathi A, Alexandrou-Athanassoulis H, et al. Pitted keratolysis in an adolescent, diagnosed using conventional and molecular microbiology and successfully treated with fusidic acid. Eur J Dermatol 2014; 24:499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim B, Park K, Kim J, et al. Comparative study of benzoyl peroxide versus clindamycin phosphate in treatment of pitted keratolysis. Korean J Med Mycol 2005; 20:144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leeyaphan C, Bunyaratavej S, Taychakhoonavudh S, et al. Cost-effectiveness analysis and safety of erythromycin 4% gel and 4% chlorhexidine scrub for pitted keratolysis treatment. J Dermatolog Treat 2019; 30:627.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leung AK, Barankin B. Palmar hyperhidrosis. J Neonatol Clin Pediatr 2014; 1:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leung AK. Botulinum toxin therapy for hyperhidrosis. Int J Dermatol 2000; 39:160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kontochristopoulos G, Sidiropoulou P, Tzanetakou V, et al. Managing pitted keratolysis: consider topical glycopyrrolate. Clin Exp Dermatol 2019; 44:713.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 16555 Version 10.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15606827" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Plantar hyperhidrosis and pitted keratolysis treated with botulinum toxin injection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3157536" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Occupational pitted keratolysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16335871" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Prevalence of skin diseases among male adolescent and post-adolescent boarding school students in Turkey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16394424" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Pitted keratolysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16394424" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Pitted keratolysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19935134" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : The use of a clindamycin 1%-benzoyl peroxide 5% topical gel in the treatment of pitted keratolysis: a novel therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28211437" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Pitied Keratolysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27294050" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Clinical and epidemiological features of coryneform skin infections at a tertiary hospital.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18937649" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Corynebacterium-associated skin infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26437161" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Pitted keratolysis: successful management with mupirocin 2% ointment monotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25386314" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Plantar pitted keratolysis: a study from non-risk groups.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24703267" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Pitted keratolysis, erythromycin, and hyperhidrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16394434" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Dermatoses among paddy field workers--a descriptive, cross-sectional pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22882561" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Pitted keratolysis; physicians' treatment and their perceptions in Dutch army personnel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11122066" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Keratolysis sulcata (pitted keratolysis): clinical symptoms with different histological correlates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29951993" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Clinical manifestations, risk factors and quality of life in patients with pitted keratolysis: a cross-sectional study in cadets.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29951993" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Clinical manifestations, risk factors and quality of life in patients with pitted keratolysis: a cross-sectional study in cadets.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19395123" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Primary hyperhidrosis increases the risk of cutaneous infection: a case-control study of 387 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25712956" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Pitted keratolysis: an infective cause of foot odour.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3243369" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Pitted keratolysis: a manifestation of human dermatophilosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12392527" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Kytococcus sedentarius, the organism associated with pitted keratolysis, produces two keratin-degrading enzymes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3310909" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Pitted keratolysis. The role of Micrococcus sedentarius.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26316369" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Pitted Keratolysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6837400" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Pitted keratolysis: a common foot problem.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9602235" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Pitted keratolysis: a discussion of two cases in non-weight-bearing areas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20086944" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Pitted keratolysis: a common infection of active feet.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22512412" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Skin manifestations of athletes competing in the summer olympics: what a sports medicine physician should know.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26982791" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Pitted keratolysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6757285" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Pitted and ringed keratolysis. A review and update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24725039" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Pitted keratolysis: a clinical review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4172480" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Ringed keratolysis of the palms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5822335" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Symptomatic pitted keratolysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1488374" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Painful, plaque-like, pitted keratolysis occurring in childhood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6852334" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Crateriform depression--an unusual clinical expression of pitted keratolysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7174913" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Coexistent erythrasma, trichomycosis axillaris, and pitted keratolysis: an overlooked corynebacterial triad?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9292083" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Pitted keratolysis: clinical manifestations in 53 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9292083" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Pitted keratolysis: clinical manifestations in 53 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21076687" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Dermoscopy of Pitted Keratolysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24898328" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Pitted keratolysis in an adolescent, diagnosed using conventional and molecular microbiology and successfully treated with fusidic acid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Comparative study of benzoyl peroxide versus clindamycin phosphate in treatment of pitted keratolysis
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30415588" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Cost-effectiveness analysis and safety of erythromycin 4% gel and 4% chlorhexidine scrub for pitted keratolysis treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Palmar hyperhidrosis
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10733329" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Botulinum toxin therapy for hyperhidrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30515854" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Managing pitted keratolysis: consider topical glycopyrrolate.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
